Kestra Medical Technologies Inc's stock experienced a significant after-hours plunge of 5.11% following the release of its third-quarter fiscal 2026 financial results.

The company reported a mixed performance for the quarter, with revenue of $24.6 million beating analyst estimates of $22.9 million and representing 63% year-over-year growth. However, the stock's negative reaction appears driven by misses on key profitability metrics, including an EPS of -$0.61 that fell short of the -$0.59 consensus estimate and an adjusted EBITDA loss of $21.2 million that was wider than the $20.7 million loss analysts had anticipated.

Despite raising its full-year revenue guidance to $93 million from $91 million previously, investors focused on the company's widening net loss of $34.2 million compared to $21.8 million in the prior year period. The after-hours selloff suggests market concerns about the company's path to profitability despite strong top-line growth and market share expansion in the wearable cardioverter defibrillator segment.